EMEA-001175-PIP01-11-M04
Key facts
| Invented name |
Eperzan
|
| Active substance |
Albiglutide
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0272/2016
|
| PIP number |
EMEA-001175-PIP01-11-M04
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Glaxo Group Limited
E-mail: eu.paediatrics-plans@gsk.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|